<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">
Longevity Logo
etc.venues 200 Aldersgate, London
February 4, 2019
 

Longevity Leaders Conference

08.00 Arrival & Welcome
Coffee, refreshments, pastries, 1-2-1 meetings and networking.

THE FUTURE OF AGEING

09.00 Opening remarks: Why Longevity Leaders? Why now?
Terry O’Dwyer, Founder, Longevity Leaders

============

09.05 Keynote Panel Discussion: The Future of the Science of Aging
  • What are the new frontiers in the biology of aging and the future of longevity science?
  • What are the limits of treating aging as a unitary disease? What are the key success factors?
  • How can technology and industry collaborations drive successful outcomes in longevity science?

Aubrey de GreyCSO, SENS Research Foundation and VP, AgeX Therapeutics
Robert Hariri, 
CEO, Celularity
Michael West, CEO, AgeX Therapeutics
Alex Zhavoronkov, CEO, Insilico Medicine
Robert Hariri
, CEO, Celularity
Sree Kant
, Head of Business Development, Life Biosciences

============

09.45 Investor Keynote: Navigating the valley of death and reaping the longevity dividend

  • Discoveries in aging biology are ready for acceleration to the clinic, where they can treat age-related disease and extend healthy lifespan. However, they must face the challenges of the ‘valley of death’ in funding, capital market vicissitudes, company creation and growing pains. Apollo Ventures is one of the leading investors in these technologies, and will share their vision of how investors can drive the industry forward and reap dividends for all.

James Peyer, CEO, Apollo Ventures

============

10.00 Keynote: A new model for commercialization of Aging R&D

  • Is the traditional VC route the most viable and productive approach to translate R&D in Aging? Life Biosciences, led by Tristan Edwards, is a brand new company chaired by David Sinclair, with Nir Barzilai as CMO that is breaking the mould with a novel approach to Aging research commercialization.

Tristan Edwards, CEO, Life Biosciences

============

10.15 Keynote:  Getting Ready for 100 - Unlocking the keys to Health, Wealth and Work in the age of longevity

  • How can various stakeholders better collaborate to help people live well and live longer?
  • What is the role of insurers, and financial service industry leaders?
  • What can be done to help society shift to prevention strategies, and prepare for retirement in the age of longevity?

Wilf Blackburn, CEO,, Prudential Assurance Company Singapore, Prudential


============

10.30 Keynote Panel Discussion: Realising the potential of the Longevity Industry Revolution

  • What are the partnerships needed to create value and maximise the commercial and business opportunities of longevity?
  • How can technology collaborations drive successful outcomes in healthcare delivery?
  • How can insurers rise to the challenge of balancing longevity risk and opportunity?
  • What are the business model innovations in R&D, Care, Consumer and Financial Services necessary to ensure success?
  • How can we reimagine our workforces and workplaces in an age of longevity?

Eric Kihlstrom, Tech entrepreneur, Former Interim Director, Healthy Ageing Industrial Strategy Challenge Fund
John Godfrey, Head of Corporate, Legal & General
James Peyer, CEO, Apollo Ventures 

============

11.10 Networking & Coffee Break

LONGEVITY R&D CONFERENCE AND SHOWCASE

11.30 The Future of Geroscience
Joao Pedro de Magalhaes, Scientist & Futurist, University of Liverpool

LONGEVITY COMPANY SHOWCASE

Presentations from CEOs of companies leading the charge in developing therapeutics, diagnostics, products or services to address the challenges of ageing.

11:45 Robert Hariri, CEO, Celularity

12:00 Kelsey Moody, CEO, Ichor Therapeutics

12:15 Peter de Keizer, CEO, Cleara Biotech

12:30 Marc Ramis Castelltort, CEO, Senolytx

12:45 Reason, CEO, Repair Biotechnologies

THE BUSINESS AND TECHNOLOGY OF LONGEVITY FORUM

11.30 The Business of Prevention & the Future of Wellbeing

Open to:

  • Healthtech, CareTech, AgeTech companies and solution providers
  • Consumer Innovation leaders and KOL's
  • Health and care providers
  • Business leaders and policy makers

Session One: The Business of Prevention and the Future of Wellbeing (45m)

 Discussion Questions

  • How can we innovate to create the homes, design, technology, products and services for the older demographic?
  • What do the care homes of the future look like?
  • How do we move from a focus on treatment, to one on prevention?
  • What is the role of government and other key stakeholders?

Session Two: Data and Connected Healthcare (45m)

 Discussion Questions

  • What are the connected and digital solutions that will prevail?
  • How can enabling tech like AI, big data and multi-omics revolutionise  business models? 

Co-Chairs:

  • Tina Woods, CEO, Collider Health
  • Eric Kihlstrom, Tech entrepreneur, Former Interim Director, Healthy Ageing Industrial Strategy Challenge Fund

 Discussants:

  • Paul Gaudin, Medtech/insurtech entrepreneur and Investor; Founder, CareRooms
  • Andrew Fried, Life Sciences Global Industry Leader, IBM
  • Joe Tighe, Head of Strategic Development, Benevolent AI
  • Anna Dixon, CEO, Centre for Aging Better

FINANCIAL SERVICES & LONGEVITY RISK FORUM

11.30 How Will the Financial Services Industry Rise to the Longevity Challenge?

Open to:

  • Financial service industry leaders (insurers, regulator, pension scheme, asset managers)
  • Ageing R&D and Biotech KOL's
  • Genomics & Precision medicine KOL's (big breakthroughs)

Format:

  • 2x 10 min presentations that set the scene
  • 2 x case studies
  • General Discussion

The drivers, breakthroughs and emerging trends of longevity

Aubrey de Grey, CSO, SENS Research Foundation, & VP, AgeX Therapeutics

New Perspectives on Derisking Longevity: An Overview

Steven Baxter, Head of Longevity Research, Club Vita

New Perspectives on Derisking Longevity: An Overview

13.00 Lunch & Networking 

R&D FORUM

14.00 Geroscience Innovation

What’s at the cutting edge of Aging R&D? How can we accelerate R&D and the advancement of new therapies to address ageing and age-related disease?

Chair:
Lynne Cox, Biochemist, University of Oxford

Discussants:
Brian Delaney, President, Age Reversal Network
Tristan Edwards, CEO, Life Biosciences Inc

15.00 Precision Medicine and Genomic Promise

How can we further advance diagnostic and precision medicine technologies and solutions?

Co-Chairs:
Joanne Hackett, Chief Commercial Officer, Genomics England
Chas Bountra, Pro-Vice Chancellor for Innovation, University of Oxford; Chief Scientist, Structural Genomics Consortium

BIOTECH BUILDING FORUM

14.00 Building The Biotechs Of Aging

How can biotechs addressing ageing and age-related disease access capital, partners and technology to advance their pipeline? What are the alternative financing tools? What are the latest innovative deal making strategies?

Chair:
Terry O’Dwyer, Founder, Longevity Leaders

Case studies:

Matthew Scholz, CEO, Oisin Biotechnology
Peter de Keizer, Founder, Cleara Biotech

Discussants
Mark Hammond, Founder, Deep Science Ventures
Sergio Ruiz, Managing Director, Methuselah Fund
Mark Allen, CEO, Elevian
Michael West, CEO, AgeX Therapeutics
Joseph Antoun, Chairman & CEO, L-Nutra
Thomas Hughes, CEO, Navitor

LONGEVITY RISK FORUM

14.00 Defining A New Model for Longevity Risk

How do we come up with a useful model for derisking longevity? How can we define breakthrough or trigger events to define longevity for the financial services industry?

Chair:
Wilf Blackburn, Chief Executive Officer, Prudential Assurance Company Singapore

Discussants:

Steven Baxter, Head of Longevity Research, Club Vita
Wilf Blackburn, Chief Executive Officer, Prudential Assurance Company Singapore
Jennifer Donohue, Director, Algorith and Extremal Consulting
John Godfrey, Head of Corporate, Legal & General
Luca Tres, Partner, Head of Life, Securis Investment Partners

16.00 Networking & Coffee Break

LONGEVITY CONFERENCE

16:15 Keynote Panel: The funding crisis in basic science

  • It is a common misconception that people think basic science is well funded via the grant system or other government funds. Unfortunately, the traditional sources of funding often focus on lower risk approaches or single diseases rather than focusing on the core mechanisms of aging and repair based approaches. Why is this and how can we address this problem?
    How does this lack of funding for fundamental research affect the development of biotech startups focused on targeting aging?
    What is the right balance between supporting basic research and investing in startups?

James Peyer, CEO, Apollo Ventures
Aubrey de Grey, CSO, SENS Research Foundation and VP, AgeX Therapeutics
Peter de Keizer, CEO, Cleara Biotech

16:55 Closing Keynote Panel: The Investment Opportunity: How can investors reap a longevity dividend

Sergey Young, Founder, Longevity Vision Fund
Xinhong Lim, Director, Vickers Ventures Partners
James Peyer, CEO, Apollo Ventures
Sergio Ruiz, Managing Director, Methuselah Fund

LONGEVITY COMPANY SHOWCASE

Presentations from CEOs of companies leading the charge in developing therapeutics, diagnostics, products or services to address the challenges of ageing.

Joseph Antoun, Chairman & CEO, L-Nutra
Thomas Hughes, CEO, Navitor
Mark Allen, CEO, Elevian
RESERVED
RESERVED 

17:30 Closing Remarks

NETWORKING DRINKS

Details coming soon.

DOWNLOAD BROCHURE

Never Miss An Update

Sign up to event updates to hear about new speakers, promotions, congress news and networking events.